PMID- 18790454
OWN - NLM
STAT- MEDLINE
DCOM- 20081118
LR  - 20080915
IS  - 1521-6926 (Print)
IS  - 1521-6926 (Linking)
VI  - 21
IP  - 3
DP  - 2008 Sep
TI  - Targeting haematopoietic-specific minor histocompatibility antigens to 
      distinguish graft-versus-tumour effects from graft-versus-host disease.
PG  - 543-57
LID - 10.1016/j.beha.2008.06.001 [doi]
AB  - Allogeneic stem cell transplantation (allo-SCT) and donor lymphocyte infusions 
      can induce durable remission in patients with haematological malignancies through 
      a graft-versus-tumour (GvT) effect. In human leukocyte antigen (HLA)-matched 
      settings, this powerful immunotherapeutic effect is predominantly mediated by 
      donor T cells directed at the recipient's minor histocompatibility antigens 
      (mHags) presented on malignant cells. The mHags are short peptides excised from 
      polymorphic regions of intracellular proteins, and are presented by HLA molecules 
      to donor T cells. Several ubiquitously expressed mHags are involved not only in 
      GvT but also in graft-versus-host disease (GvHD). However, a specific set of 
      mHags is expressed exclusively by haematopoietic cells and their malignant 
      counterparts. Targeting these haematopoietic mHags is an attractive strategy to 
      induce specific GvT effects without increasing the risk of GvHD. This chapter 
      will summarize the current efforts to identify therapeutically relevant 
      haematopoietic mHags, and outline the strategies to apply mHag-based cellular 
      immunotherapy to treat recurrent malignancies after allo-SCT.
FAU - Spaapen, Robbert
AU  - Spaapen R
AD  - Department of Clinical Chemistry and Haematology, University Medical Center 
      Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
FAU - Mutis, Tuna
AU  - Mutis T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Haematol
JT  - Best practice & research. Clinical haematology
JID - 101120659
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA Antigens)
RN  - 0 (Minor Histocompatibility Antigens)
SB  - IM
MH  - Cancer Vaccines/therapeutic use
MH  - Dendritic Cells/*immunology/transplantation
MH  - Diagnosis, Differential
MH  - Graft vs Host Disease/diagnosis/*immunology
MH  - Graft vs Tumor Effect/*immunology
MH  - HLA Antigens/immunology
MH  - Histocompatibility Testing/methods
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - Minor Histocompatibility Antigens/*immunology
RF  - 90
EDAT- 2008/09/16 09:00
MHDA- 2008/11/19 09:00
CRDT- 2008/09/16 09:00
PHST- 2008/09/16 09:00 [pubmed]
PHST- 2008/11/19 09:00 [medline]
PHST- 2008/09/16 09:00 [entrez]
AID - S1521-6926(08)00052-2 [pii]
AID - 10.1016/j.beha.2008.06.001 [doi]
PST - ppublish
SO  - Best Pract Res Clin Haematol. 2008 Sep;21(3):543-57. doi: 
      10.1016/j.beha.2008.06.001.